Previous Close | 172.32 |
Open | 172.34 |
Bid | 172.36 x 1100 |
Ask | 172.40 x 1100 |
Day's Range | 172.32 - 172.46 |
52 Week Range | 21.83 - 172.46 |
Volume | |
Avg. Volume | 954,093 |
Market Cap | 6.566B |
Beta (5Y Monthly) | 1.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.62 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 172.45 |
Subscribe to Yahoo Finance Plus to view Fair Value for RETA
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […]
PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen").
Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would...